Two Sigma Advisers
ALLO icon

Two Sigma Advisers’s Allogene Therapeutics ALLO Stock Holding History

Two Sigma Advisers’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,890,200
Closed -$3.96M – 87
2025
Q4 		$3.96M Buy
2,890,200
+108,600
+4% +$143K 0.01% 923
2025
Q3 		$3.45M Buy
2,781,600
+1,014,200
+57% +$1.21M 0.01% 888
2025
Q2 		$2M Sell
1,767,400
-433,400
-20% -$576K ﹤0.01% 1120
2025
Q1 		$3.21M Sell
2,200,800
-501,400
-19% -$945K 0.01% 966
2024
Q4 		$5.76M Buy
2,702,200
+291,800
+12% +$720K 0.01% 665
2024
Q3 		$6.75M Buy
2,410,400
+167,900
+7% +$448K 0.02% 607
2024
Q2 		$5.23M Buy
2,242,500
+911,400
+68% +$2.69M 0.01% 739
2024
Q1 		$5.95M Buy
1,331,100
+53,400
+4% +$223K 0.01% 709
2023
Q4 		$4.1M Buy
1,277,700
+300,500
+31% +$852K 0.01% 902
2023
Q3 		$3.1M Sell
977,200
-237,500
-20% -$1.04M 0.01% 966
2023
Q2 		$6.04M Sell
1,214,700
-80,100
-6% -$433K 0.02% 682
2023
Q1 		$6.4M Buy
1,294,800
+334,400
+35% +$2.14M 0.02% 713
2022
Q4 		$6.04M Buy
960,400
+737,900
+332% +$6.83M 0.02% 706
2022
Q3 		$2.4M Buy
222,500
+90,000
+68% +$1.22M 0.01% 1076
2022
Q2 		$1.51M Sell
132,500
-100,000
-43% -$888K ﹤0.01% 1370
2022
Q1 		$2.12M Buy
+232,500
New +$2.42M 0.01% 1226
2021
Q3 		– Sell
-67,800
Closed -$1.77M – 2426
2021
Q2 		$1.77M Sell
67,800
-346,300
-84% -$9.88M ﹤0.01% 1350
2021
Q1 		$14.6M Buy
414,100
+62,300
+18% +$2.1M 0.04% 438
2020
Q4 		$8.88M Buy
351,800
+14,300
+4% +$466K 0.02% 607
2020
Q3 		$12.7M Buy
337,500
+305,300
+948% +$11.5M 0.04% 461
2020
Q2 		$1.38M Buy
+32,200
New +$1.16M ﹤0.01% 1415

Other funds holding ALLO

P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Advisers's ALLO Position: Q1 2026 in Review

Two Sigma Advisers sold out of Allogene Therapeutics (ALLO) in Q1 2026, closing a stake of 2,890,200 shares — an estimated $3.96M sold.

Two Sigma Advisers first reported a position in ALLO in Q2 2020 and held it in 21 quarters. The position peaked at $14.6M in Q1 2021. 209 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • Two Sigma Advisers reported no remaining Allogene Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 2,890,200 Allogene Therapeutics shares in Q1 2026, an estimated $3.96M.
  • Two Sigma Advisers first reported a position in Allogene Therapeutics in Q2 2020 and held it in 21 quarters.
  • Two Sigma Advisers's Allogene Therapeutics position peaked at $14.6M in Q1 2021.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.